INTRODUCTION

Mucormycosis or black fungus is an uncommon fungal infection that affects usually immunocompromised patients such as patients with diabetes, renal dysfunction, cancer, or under immunosuppressive therapy. It is due to a non-septate filamentous fungus that affects often facial structures (nose, sinuses, eye, and brain), lungs, or skin and less commonly the gastrointestinal tract, the stomach being on the top of the list. The major route of infection transmission is inhalation. However, when it concerns the gastrointestinal tract, ingestion of filaments is incriminated. The clinical signs usually depend on the site of origin. Treatment is based on amphotericin B and in most cases surgical debridement of necrotic tissues, though mucormycosis is associated with poor prognosis and high rates of mortality.1

CASES PRESENTATION

2.1 | Case one

A 61-year-old Tunisian woman with type 2 diabetes mellitus, hypertension, dyslipidemia, and family history of peptic ulcer presented to our gastroenterology department with a 7-day history of vomiting preceded by a 4-month history of
dry cough for which she took inhaled corticosteroids. On physical examination, she had no fever, her body mass index was 29.8 kg/m². Her blood pressure was 120/70 mmHg. Her abdominal exam was normal. Initial laboratory tests showed renal dysfunction with creatinine level at 163 μmol/L and creatinine clearance at 60 ml/min, hemoglobin was 11.5 g/dl, white blood cell count (WBC) 11,100 cells/μl, C-reactive protein (CRP) 132 g/L, and blood sugar 20 mmol/L (Table 1).

Upper gastrointestinal endoscopy revealed budding and infiltrating grayish process resting on an ulcerated fundic mucosa (Figure 1).

Anatomopathological exam concluded invasive mucormycosis by demonstrating zygomycosis hyphae without any malignant signs (Figure 2). These findings were confirmed by parasitological examination (Figure 3).

A brain-face-chest-abdomen and pelvis computed tomography and ENT exam were practiced to search other sites of mucormycosis (Figure 4). They confirmed the presence of other infection site.

Since the liposomal form of amphotericin B which is less nephrotoxic was not available in our country, therapy based on conventional amphotericin B was started on the fifth day of diagnosis at progressive dose 5 mg/day on day one until 25 mg/day (0.4 mg/kg/day) on day 5. Evolution was marked by an aggravation of renal dysfunction: creatinine level increased to 208 μmol/L and creatinine clearance decreased to 25 ml/min. Thus, we stopped antifungal therapy. In day 19, she was programmed for a total gastrectomy but presented a respiratory distress due to pulmonary embolism. The patient underwent total gastrectomy 2 months after diagnosis. The examination of the stomach showed two digging ulcers in the fundus (Figure 5). The patient died 10 days after surgery.

### 2.2 | Case two

A 59-year-old man originally from Cango living in Tunisia without any medical history presented to the hospital with gastric pain and vomiting and a fast worsening of the general state. At admission, he had fever. He had low blood pressure (80/45 mmHg) and tachycardia (110 BPM). Abdominal exam showed epigastric tenderness and a moderate ascites. Laboratory findings revealed severe normocytic anemia with 7.1 g/dl hemoglobin, elevated WBC count (24,900 cells/μl [93% neutrophils]), and thrombocytopenia at 72,000/mm³. He had high CRP (231 g/L) with positive procalcitonin test (2.53 ng/ml). We concluded a septic shock, and the patient had broad-spectrum antibiotic therapy and vascular filling with vasoactive drugs.

Upper gastrointestinal endoscopy revealed a very fragile mucosa and a gastric ulcer with bleeding stigmata (Figure 6). Abdominal ultrasound was normal besides moderate ascites. Anatomopathological exam showed typical broad zygomycetes hyphae (Figure 7).

Six days later, the patient developed an hemophagocytic syndrome confirmed by cytological examination of the bone marrow. Evolution was rapidly fatal with continuous decrease in hemoglobin level despite transfusions, and the patient died within 8 days after admission.

### 3 | DISCUSSION

Zygomycosis was first described as a cause of human disease in 1885. Unlike other fungal opportunistic infections affecting patients with compromised immunity, cancer, or recipients

**TABLE 1** Laboratory test results on admission

| Laboratory test       | Results | Reference range |
|-----------------------|---------|-----------------|
| Urea (mmol/L)         | 15.5    | 2.5–7.6         |
| Creatinine (μmol/L)   | 163     | 50–100          |
| Clearance (ml/min)    | 30      | >90             |
| Hemoglobin (g/dl)     | 11.5    | 12–17           |
| WBC (cells/mm³)       | 11,100  | 4500–10,000     |
| Platelets (cells/mm³) | 252,000 | 150,000–400,000 |
| CRP (g/L)             | 132     | <6              |
| Sodium (mmol/L)       | 134     | 136–145         |
| Albumin (g/L)         | 29      | 38–46           |
| Blood sugar (mmol/L)  | 20      | 3.5–6.1         |

**FIGURE 1** Upper gastrointestinal endoscopy showing budding and infiltrating grayish process.
of organ transplant, mucormycosis can occur in patients with diabetes mellitus,\textsuperscript{2–4} renal insufficiency, alcoholism,\textsuperscript{5–7} or even with an intact immunity system.\textsuperscript{8–10} These underlying conditions not only predispose to the disease but also worsen the outcome of patients. Our first patient had diabetes and renal insufficiency as risk factors of mucormycosis.\textsuperscript{10}

The mode of transmission of mucormycosis involves inhalation or ingestion of spores and direct inoculation into damaged mucocutaneous surfaces.\textsuperscript{9}

The common sites of infection are sinuses (39%) which constitute the predilected infection site in diabetic patients, skin (19%) in particular in patients with no risk factor, and lungs (24%) in patients with cancer.\textsuperscript{2,11}

The gastrointestinal tract is less commonly affected (7%) with 67% of stomach infection and 25% of intestine infection.\textsuperscript{2,10} Factors predisposing for gastrointestinal

![FIGURE 2](image2.png) (A, B) Necrotic and inflammatory material comprising mycelial filaments suggesting mucormycosis.

![FIGURE 3](image3.png) (A) Microscopic exam in lactophenol showing large, irregular, and non-septate hyphae. (B) Microscopic exam after culture showing the rhizoids and the columella specific for the species \textit{Rhizopus arrhizus}.

![FIGURE 4](image4.png) CT scan of abdomen showing fundic mucosal thickening.

![FIGURE 5](image5.png) Resected stomach showing 2 ulcers in the fundus.
mucormycosis (GIM) include malnutrition, typhoid fever, uremia, and penetrating trauma.\textsuperscript{9,12}

The clinical manifestations of GIM include fever, abdominal pain, nausea, vomiting, diarrhea, hemorrhage, or gastrointestinal perforation.\textsuperscript{9,13} Our first patient presented only vomiting, and the second patient presented with fever, abdominal pain, and vomiting. The confirmation of diagnosis is based on anatomopathological examination of tissue samples showing fungal hyphae.\textsuperscript{9,14}

GIM is usually fatal with 85\% of mortality.\textsuperscript{2,11,15} The mainstay of therapy in GIM is a combination of surgical debridement and intravenous antifungal therapy. Early initiation of antifungal therapy improves survival and can even exempt the patient from surgery in case of non-invasive form of the disease.\textsuperscript{11} A delay in treatment greater than 6 days worsens the prognosis and seems to double the mortality rates.\textsuperscript{9} The cornerstone of drug therapy is amphotericin B which constitutes the first line treatment at a daily dose of 1 to 1.5 mg/kg for a duration of 4–6 weeks.\textsuperscript{5,9,16} The liposomal form is preferred for its lower risk of nephrotoxicity and the possibility to administrate higher doses: 5 to 10 mg/kg/day.\textsuperscript{2,17,18} Posaconazole and isavuconazole are also effective agents and can be used as second-line therapy. Surgical debridement of necrotic tissues is often required for invasive mucormycosis.\textsuperscript{1,18} In our country; thus, we started treatment with conventional amphotericin B at low doses which was stopped at the 5th day because of worsening of renal dysfunction, and we opted for the surgical debridement. As for the second patient, he did not receive this treatment since he was in a septic shock.

4 | CONCLUSION

Gastric mucormycosis is a rare entity that affects usually predisposed patients such as immunocompromised, alcoholic, and diabetic patients. However, immunocompetent patients are not spared. Its treatment is based on amphotericin B and surgical debridement of all necrotic tissues. The mortality rates remain high up to 85\%. Thus, early diagnosis and prompt therapy are necessary to improve prognosis.

AUTHOR CONTRIBUTIONS

Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data: Manel Moalla, Salwa Nechi, Amina Bani, Aicha Elloumi, Sana Jemal. Been involved in drafting the manuscript or revising it critically for important intellectual content: Amal Khhiba, Manel Moalla. Given final approval of the version to be published. Each author should

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure6}
\caption{Endoscopy showing fragile mucosa and a gastric ulcer with bleeding stigmata.}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure7}
\caption{(A) Typical broad zygomycetes hyphae branching at right angle (PAS, 400x). (B) Zygomycetes hyphae within the gastric mucosa.}
\end{figure}
have participated sufficiently in the work to take public responsibility for appropriate portions of the content: Mohamed Moussaddek Azouz. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: Amal Khsiba, Manel Moalla, Mohamed Moussaddek Azouz.

ACKNOWLEDGMENTS

None.

FUNDING INFORMATION

None.

CONFLICT OF INTEREST

We have no conflict of interest to declare.

DATA AVAILABILITY STATEMENT

Data openly available in a public repository that issues datasets with DOIs.

ETHICAL APPROVAL

Patient personal data have been respected.

CONSENT

Written informed consent was obtained from the patients to publish this report in accordance with the journal's patient consent policy.

ORCID

Manel Moalla https://orcid.org/0000-0002-5828-0469

REFERENCES

1. Janjua OS, Shaikh MS, Fareed MA, et al. Dental and oral manifestations of COVID-19 related mucormycosis: diagnoses, management strategies and outcomes. J Fungi (Basel). 2021;8(1):44.
2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653.
3. Vazquez JA, Sobel JD. Fungal infections in diabetes. Infect Dis Clin North Am. 1995;9:97-116.
4. Meyer RD, Armstrong D. Mucormycosis changing status. CRC Crit Rev Clin Lab Sci. 1973;4:421-451.
5. Ho Y-H, Wu B-G, Chen Y-Z, Wang L-S. Gastric Mucormycosis in an alcoholic with review of the literature. Tzu Chi Med J. 2007;19(3):169-172.
6. Park YS, Lee JD, Kim TH, et al. Gastric mucormycosis. Gastrointest Endosc. 2002;56:904-905.
7. Shahapure AG, Patankar RV, Bhatkhande R. Gastric mucormycosis. Indian J Gastroenterol. 2002;21:231-232.
8. Abreu BFBB, Duarte ML, dos Santos LR, Sementilli A, Figueiras FN. Gastric mucormycosis in an immunocompetent patient. Rev Soc Bras Med Trop. 2018;51(3):401-402.
9. Sehmbev G, Malik R, Kosa D, Srinivasan I, Chuang KY, Bellapralvalu S. Gastric ulcer and perforation due to Mucormycosis in an immunocompetent patient. ACG Case Rep J. 2019;6:1-3.
10. Abdi BatiWotije KSP, Ayele BA. Invasive intestinal mucormycosis in a 40-year old immunocompetent patient – a rarely reported clinical phenomenon: a case report. BMC Gastroenterology. 2020;20:61.
11. Adhikari S, Gautam AR, Paudyal B, Sigdel KR, Basnyat B. Case report: gastric Mucormycosis- a rare but important differential diagnosis of upper gastrointestinal bleeding in an area of helicobacter pylori endemcity. Wellcome Open Res. 2019:4:5.
12. Lelievre L, Garcia-Hermoso D, Abdoul H, et al. Posttraumatic mucormycosis: a nationwide study in France and review of the literature. Medicine (Baltimore). 2014;93(24):395-404.
13. Lo OS, Law WL. Ileocolonic mucormycosis in adult immunocompromised patients: a surgeon's perspective. World J Gastroenterol. 2010;16(9):1155-1170.
14. Song BI. F-18 fluorodeoxyglucose positron emission tomography/computed tomography image of gastric mucormycosis mimicking advanced gastric cancer: a case report. World J Clin Cases. 2019;7(10):1155-1160.
15. Agha FP, Lee HH, Boland CR, Bradley SF. Mucormycoma of the colon: early diagnosis and successful management. AJR Am J Roentgenol. 1985;145(4):739-741.
16. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126-133.
17. Cornely OA, Arikian-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5-26.
18. Malek A, De la Hoz A, Arduino R, Aisenberg GM. Disseminated tuberculosis and gastric mucormycosis coinfection. IDCases. 2019;18:e00595.

How to cite this article: Khsiba A, Moalla M, Nechi S, et al. Fatal invasive gastric mucormycosis: Two case reports. Clin Case Rep. 2022;10:e06330. doi: 10.1002/ccr3.6330